Research on the regulation of oral microecological balance and antimicrobial peptide LL-37-related inflammatory circuit in patients with palmoplantar pustulosis by dehumidification and detoxification

注册号:

Registration number:

ITMCTR2025001530

最近更新日期:

Date of Last Refreshed on:

2025-07-30

注册时间:

Date of Registration:

2025-07-30

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

除湿解毒法对掌跖脓疱病患者口腔微生态平衡及抗菌肽LL-37相关炎症环路的调控研究

Public title:

Research on the regulation of oral microecological balance and antimicrobial peptide LL-37-related inflammatory circuit in patients with palmoplantar pustulosis by dehumidification and detoxification

注册题目简写:

English Acronym:

研究课题的正式科学名称:

除湿解毒法对掌跖脓疱病患者口腔微生态平衡及抗菌肽LL-37相关炎症环路的调控研究

Scientific title:

Observation on the efficacy of dehumidification and detoxification method in the treatment of palmoplantar pustulosis: a self-controlled before-after study based on oral microecological balance and antimicrobial peptide LL-37-related inflammatory circuit

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈泽慧

研究负责人:

王俊慧

Applicant:

Chen Zehui

Study leader:

Wang Junhui

申请注册联系人电话:

Applicant telephone:

18811505175

研究负责人电话:

Study leader's telephone:

13264396702

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zehuijzl01@163.com

研究负责人电子邮件:

Study leader's E-mail:

747191432@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京东城区东直门内南小街16号

研究负责人通讯地址:

北京市西城区广安门内大街北线阁5号

Applicant address:

Dongzhimen South Street No. 16

Study leader's address:

No. 5 Beixiange Guang'anmen Nei Avenue Xicheng District

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国中医科学院中医药信息研究所

Applicant's institution:

Institute of Information on Traditional Chinese Medicine China Academy of Chinese Medical Sciences

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2022-206-KY-01

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

中国中医科学院广安门医院伦理委员会

Name of the ethic committee:

Ethics Committee of Guang'anmen Hospital China Academy of Chinese Medical Sciences

伦理委员会批准日期:

Date of approved by ethic committee:

2022/10/26 0:00:00

伦理委员会联系人:

乔洁

Contact Name of the ethic committee:

Qiao Jie

伦理委员会联系地址:

北京市西城区广安门内大街北线阁5号 中国中医科学院广安门医院

Contact Address of the ethic committee:

No. 5 Beixiange Guang'anmen Nei Avenue Xicheng District

伦理委员会联系人电话:

Contact phone of the ethic committee:

010-88001552

伦理委员会联系人邮箱:

Contact email of the ethic committee:

gamhec@126.com

研究实施负责(组长)单位:

中国中医科学院广安门医院

Primary sponsor:

No. 5 Beixiange Guang'anmen Nei Avenue Xicheng District

研究实施负责(组长)单位地址:

北京市西城区广安门内大街北线阁5号

Primary sponsor's address:

No. 5 Beixiange Guang'anmen Nei Avenue Xicheng District

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院广安门医院

具体地址:

北京市西城区广安门内大街北线阁5号

Institution
hospital:

Guang'anmen Hospital China Academy of Chinese Medical Sciences

Address:

No. 5 Beixiange Guang'anmen Nei Avenue Xicheng District

经费或物资来源:

中国中医科学院

Source(s) of funding:

China Academy of Chinese Medical Sciences

研究疾病:

掌跖脓疱病

研究疾病代码:

Target disease:

Palmoplantar pustulosis

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

单臂

Single arm

研究所处阶段:

Study phase:

治疗新技术临床试验

New Treatment Measure Clinical Study

研究目的:

分析掌跖脓疱病患者的口腔菌群特点,探索口腔微生物群与PPP 易感性之间的关联,明确中医药治疗掌跖脓疱病的干预效果

Objectives of Study:

To analyze the characteristics of oral microbiota in patients with palmoplantar pustulosis explore the association between oral microbiota and PPP susceptibility and explore the effective intervention mechanism of traditional Chinese medicine in the treatment of palmoplantar pustulosis through in vivo and in vitro experiments

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1. 符合掌跖脓疱病西医诊断标准者; 2. 符合掌跖脓疱病中医诊断标准者; 3. 年龄≥18岁; 4. 知情同意者

Inclusion criteria

1. Patients who meet the Western medical diagnosis criteria for palmoplantar pustulosis; 2. Patients who meet the Chinese medical diagnosis criteria for palmoplantar pustulosis; 3. Age ≥ 18 years old; 4. Patients who have given informed consent

排除标准:

1. 年龄小于18周岁者; 2. 有严重心、肝、肾、血液、消化、内分泌等系统疾病及其他皮肤病者; 3. 妊娠及哺乳期妇女; 4. 已知对治疗药物中某种成分或对照药物某种成分过敏者; 5. 1个月内曾口服维 A 酸类、免疫抑制剂、四环素类、糖皮质激素等药物治疗本病者; 6. 正在外用激素或物理疗法治疗本病者。

Exclusion criteria:

1. Individuals under the age of 18; 2. Individuals afflicted with severe cardiac hepatic renal hematological digestive endocrine and other systemic ailments in addition to dermatological conditions are also included. 3. Women who are pregnant and women who are lactating 4. Individuals with documented allergies to specific components of the therapeutic or control drug should be considered. 5. Individuals who have ingested oral retinoids immunosuppressants tetracyclines glucocorticoids or other pharmaceutical agents for the treatment of this disease within the past month are included in this study. 6. Individuals who are currently utilizing topical hormones or physical therapy as treatment for this condition.

研究实施时间:

Study execute time:

From 2022-10-26

To      2024-10-31

征募观察对象时间:

Recruiting time:

From 2022-10-27

To      2024-10-31

干预措施:

Interventions:

组别:

中药组

样本量:

30

Group:

Chinese Medicine Group

Sample size:

干预措施:

清疱除湿解毒方口服

干预措施代码:

Intervention:

Qingpao Chushi Jiedu Formula (QCJF) for oral use

Intervention code:

组别:

健康对照组

样本量:

30

Group:

Health Control Group

Sample size:

干预措施:

无任何干预

干预措施代码:

Intervention:

without any intervention

Intervention code:

样本总量 Total sample size : 60

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院广安门医院

单位级别:

副局级事业单位

Institution/hospital:

Guang'anmen Hospital China Academy of Chinese Medical Sciences

Level of the institution:

state-administered medical institution

测量指标:

Outcomes:

指标中文名:

皮损评分

指标类型:

主要指标

Outcome:

Skin Lesion Score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量评分

指标类型:

次要指标

Outcome:

Quality of life score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

瘙痒/疼痛评分

指标类型:

次要指标

Outcome:

Itch/pain score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

唾液

组织:

Sample Name:

saliva

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

舌苔

组织:

Sample Name:

Tongue coating

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

结束

Completed

年龄范围:

最小 18
Min age years
最大 90
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究非随机对照试验,不涉及随机方法

Randomization Procedure (please state who generates the random number sequence and by what method):

This study is not a randomized controlled trial and does not involve random methods

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not applicable

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

临床数据将以专为本试验设计的标准化病例报告表 (CRF) 形式记录,包括: • 中医证候评定标准 • 皮肤病变严重程度评分(例如 PASI/PppASI) • 不良事件报告表;电子数据采集 (EDC) 将通过 ResMan 进行

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Clinical data will be recorded in standardized Case Report Forms (CRFs) designed specifically for this trial including: • Traditional Chinese medicine (TCM) syndrome evaluation criteria • Skin lesion severity scores (e.g. PASI/PppASI) • Adverse event reporting forms"; "Electronic Data Capture (EDC) will be implemented via ResMan

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above